To ascertain the glioma origin of the CD133+ cell fraction in our low-grade and high-grade glioma specimens, we subsequently performed CD133 expression analysis in combination with CD45 and CD31 staining. The gene discussed is PTPRC; the disease is central nervous system cancer.